US ▾
IPIPGP

IPG Photonics (IPGP) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· May 5, 2026

Source: earnings call transcript

Executive summary

IPG Photonics Q1 FY26 — Strong Revenue Growth Driven by Battery Manufacturing and Medical

IPG Photonics delivered a strong Q1 FY26, with revenue up 17% year-over-year, driven by robust demand in battery manufacturing and medical applications. The company introduced a new reporting framework, highlighting growth in both Industrial and Advanced Solutions. Despite macroeconomic uncertainties and tariff headwinds, strong bookings and a healthy backlog provide confidence in the outlook, with a continued focus on strategic growth initiatives and operational efficiency.

Highlights

5

  • First quarter revenue exceeded expectations, increasing 17% year-over-year to $265 million.

  • Industrial Solutions revenue grew 21% year-over-year, accounting for 86% of total sales.

  • Total bookings were strong with book-to-bill firmly above 1 for the second consecutive quarter.

  • Medical revenue grew significantly year-over-year, supported by a very strong backlog for 2026.

  • North American revenue increased 27% compared with last year.

Concerns

4

  • Advanced Solutions revenue declined modestly year-over-year and 13% quarter-over-quarter due to lower micromachining and sequential medical sales.

  • GAAP operating loss was $8 million in the quarter.

  • Tariffs are expected to persist in 2026, impacting gross margin by approximately 150 basis points.

  • Underabsorbed expenses continue to run at a higher level than targeted.

Guidance & targets

CategoryTargetConfidence
Revenue
$260 million to $290 million
high materiality
High
Adjusted Gross Margin
37% and 40%
medium materiality
High
Adjusted Operating Expenses
$92 million to $95 million
medium materiality
High
Adjusted Operating Expenses
increase moderately
low materiality
Medium
Adjusted EPS
$0.25 to $0.55
high materiality
High
Adjusted EBITDA
$32 million and $48 million
medium materiality
High
Capital Expenditures
$90 million to $100 million
medium materiality
High
Medical Revenue
another good year
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Industrial Solutions
Driven by growth in welding, cutting, marking, and cleaning applications. Benefited from solid demand and new orders from battery manufacturing. Outperformed typical seasonality sequentially.
86% of total sales21%flat—
Advanced Solutions
Growth in medical and semiconductor applications was offset by lower micromachining sales due to cyclical demand in solar cell manufacturing. Sequential decline due to lower medical sales from an exceptionally strong Q4 2025.
14% of total salesmodestly declineddown 13%—
North America
Year-over-year growth driven by welding, cutting, additive manufacturing, and medical applications. Sequential decline due to lower sales in cleaning and medical, partially offset by strength in other areas.
—27%down 4%—
Europe
Year-over-year growth driven by cutting. Sequential decline due to lower sales in welding, cleaning, and additive manufacturing.
—4%down 13%—
Asia
Year-over-year growth driven by strong demand in welding, cutting, marking, and cleaning applications, primarily benefiting from capacity additions for battery manufacturing.
—14%flat—

Orderbook & backlog

Total Bookings strong Q1 FY26

firmly above 1 (book-to-bill)

Book-to-bill firmly above 1 for the second consecutive quarter, giving confidence in the outlook and pointing to robust demand.

Medical Backlog very strong Q1 FY26

Provides excellent visibility into full year 2026 revenue, pointing to another good year in medical.

Product announcements

ProductTypeDetails
Crossbowupdate
Medical productsroadmap
RAC integrated lasers with new cutting headsexpansion
Cleaning systemsexpansion

Deals & partnerships

Lockheed Martin Follow-on order for Crossbow high-energy laser defense system $10 million

Lockheed Martin placed a $10 million follow-on order for IPG's Crossbow scalable, cost-effective, high-energy laser defense system for countering Group 1 and Group 2 drone threats.

TRUMPF Laser System technique Settlement of litigation and license agreement $13.5 million

A $13.5 million payment and license related to an agreement settling all parts of litigation between the companies worldwide.

Capital programs

Major fiber manufacturing facility in Germany underway $90 million to $100 million
Period spend: $16 million

The full-year CapEx budget of $90 million to $100 million is due to investments in this facility. Q1 spend was $16 million, below the expected run rate due to timing of investments.

Risks & headwinds

Elevated macroeconomic uncertainty

not quantified

Mitigation:Remaining cautiously optimistic in outlook; focusing on executing growth strategy, operational excellence, and innovation.

Tariffs persist in 2026

150 basis points impact on gross margin

Mitigation:Working on cost reduction and pricing initiatives to offset the impact.

Underabsorbed expenses ongoing

running at a higher level than targeted

Mitigation:Specific initiatives underway to improve operational efficiency.

Geopolitical developments (Middle East)

potential influence on freight costs

Mitigation:Limited direct exposure to petrochemicals and energy markets; vertical integration provides resilience against potential adverse impacts.

Tougher comparisons in second half of 2026 H2 FY26

not quantified

Mitigation:Acknowledged by management, implying a potential deceleration in growth rates compared to a strong H2 FY25.

What to watch in Q2 FY26

Gross Margin Trajectory

next quarter and beyond
Current 37.8% (adjusted)
Target mid-40s target

Why it matters

Management reaffirmed the long-term gross margin target despite tariff headwinds, and Q2 guidance reflects momentum. Verification of continued improvement is key to profitability.

In general, that's a target we're still striving to get to. We are starting to see some of the cost reduction initiatives and some of the pricing that we talked about last year paid through.

Find out whether IPGP delivers this. Inve re-checks your case every morning.

Q&A highlights

Is the mid-40s gross margin target still valid given tariffs and input costs?

Tim Mammen affirmed that the mid-40s gross margin target remains valid. He highlighted ongoing cost reduction and pricing initiatives, along with efforts to improve absorption of fixed manufacturing costs. Tariffs are acknowledged as a 150 basis point headwind, but Q2 guidance reflects positive momentum.

“In general, that's a target we're still striving to get to. We are starting to see some of the cost reduction initiatives and some of the pricing that we talked about last year paid through.”

asked by Ruben Roy · answered by Timothy P.V. Mammen

2 min read 5 chapters

Detailed narrative

New Reporting Framework for Strategic Clarity

IPG Photonics introduced an updated revenue reporting framework, segmenting its business into Industrial Solutions (86% of Q1 revenue) and Advanced Solutions (14% of Q1 revenue). This change aims to provide clearer visibility into strategic growth initiatives by separating industrial and non-industrial revenue streams, each characterized by distinct performance and growth profiles. The company believes this new structure will enhance understanding of its market focus and progress.

Industrial Solutions Drive Strong Performance

The Industrial Solutions segment reported a 21% year-over-year revenue increase, driven by robust demand in welding, cutting, marking, and cleaning applications. A significant contributor was battery manufacturing, spanning both electric vehicles and stationary storage, which benefits from IPG's differentiated adjustable mode beam lasers and real-time process monitoring. Sequentially, Industrial Solutions revenue remained flat, outperforming typical seasonality.

Advanced Solutions Progress in High-Growth Markets

Advanced Solutions, targeting a $5 billion total addressable market across medical, defense, micromachining, and semiconductor manufacturing, saw growth in medical and semiconductor applications. This was partially offset by a decline in micromachining sales due to cyclical demand in solar cell manufacturing. The segment's sequential revenue decreased by 13% following an exceptionally strong Q4 2025 in medical sales, but the company remains optimistic about its long-term growth opportunities.

Defense and Medical Traction

In defense, IPG Photonics secured a $10 million follow-on order from Lockheed Martin for its Crossbow high-energy laser defense system, with shipments commencing in Q2. The system, designed to counter drone threats, continues to generate significant customer interest. The medical segment experienced substantial year-over-year revenue growth, driven by a new customer, and boasts a strong backlog for 2026, providing excellent full-year revenue visibility.

Focus on Operational Efficiency and Margin Improvement

Despite achieving an adjusted gross margin of 37.8% in Q1, the company is actively pursuing initiatives to improve product margins through cost reductions and pricing strategies. Tariffs remain a headwind, impacting gross margin by approximately 150 basis points, and underabsorbed expenses are higher than desired. Management is implementing specific measures to enhance operational efficiency and mitigate these pressures, aiming for a structural gross margin in the mid-40s.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.